Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from Metsera
These results suggest that GHK-Cu may alleviate the clinical symptoms of UC, emphasizing its potential as a therapeutic agent for colitis
The chart below shows Saxenda (7-9% weight loss, injected daily)) compared to Wegovy (~15% weight loss, injected weekly)
the entire processincluding evaluation, prescription, and medication deliveryis conducted through Klinic's user-friendly online platform, fully serving the Slidell community
BPC-157 is a synthetic peptide related to a protein found in the stomach
VEGF and Angiogenesis VEGF secretion increases dose-dependently in mesenchymal stem cells, mediated through integrin 1 and 1 pathways